103 related articles for article (PubMed ID: 17366795)
1. [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
Zhang XR; Zhu YZ; Xiu QY; Han FC; Liu DQ; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):777-9. PubMed ID: 17366795
[TBL] [Abstract][Full Text] [Related]
2. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
3. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
4. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
5. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].
Han N; Liu ZW; Wang J; Zhang ZM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Feb; 30(2):349-50. PubMed ID: 20159719
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
Charoentum C; Thongprasert S; Chewasakulyong B; Euathrongchit J; Sorraritchingchai S; Munprakan S
J Med Assoc Thai; 2007 Nov; 90(11):2506-12. PubMed ID: 18181342
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
Kim HT; Han JY; Lee DH; Chun JH; Lee HG; Lee JJ; Kim HY; Lee SY; Lee JS
Cancer; 2006 Aug; 107(4):799-805. PubMed ID: 16826586
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
14. [A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group].
Nagao K; Fukuoka M; Fujita A; Kurita Y; Saito R; Niitani H; Negoro S; Katakami N; Nakano M
Gan To Kagaku Ryoho; 2000 Mar; 27(3):413-21. PubMed ID: 10740635
[TBL] [Abstract][Full Text] [Related]
15. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Zhao WY; Chen DY
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):775-9. PubMed ID: 23291073
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Murren JR; Andersen N; Psyrri D; Brandt D; Nadkarni R; Rose M; Davies MJ; Parisot N; Rosenfield AT; Pizzorno G; Zelterman D
Cancer Biol Ther; 2005 Dec; 4(12):1311-5. PubMed ID: 16258263
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
19. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
20. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
